2-Oxoquazepam
| 2-Oxoquazepam | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
2-Oxoquazepam is a benzodiazepine derivative. It is a minor metabolite of the drug quazepam, which is used primarily for the treatment of insomnia.
Pharmacology[edit]
2-Oxoquazepam acts on the central nervous system by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor. This action results in sedative, hypnotic, and anxiolytic effects, which are characteristic of benzodiazepines.
Metabolism[edit]
2-Oxoquazepam is formed in the body as a metabolite of quazepam. Quazepam is metabolized in the liver by the cytochrome P450 enzyme system, particularly by the CYP3A4 and CYP2C19 isoenzymes. The primary metabolites of quazepam are 2-oxoquazepam and N-desalkyl-2-oxoquazepam.
Clinical Use[edit]
While 2-oxoquazepam itself is not marketed as a drug, its parent compound, quazepam, is used in the treatment of insomnia. Quazepam is known for its relatively long half-life and its ability to maintain sleep without significant residual effects the next day.
Side Effects[edit]
The side effects of 2-oxoquazepam are similar to those of other benzodiazepines and may include drowsiness, dizziness, fatigue, and cognitive impairment. Long-term use can lead to tolerance, dependence, and withdrawal symptoms upon discontinuation.
Legal Status[edit]
The legal status of 2-oxoquazepam is not well-defined, as it is not marketed as a standalone drug. However, its parent compound, quazepam, is classified as a Schedule IV controlled substance under the Controlled Substances Act in the United States, indicating a potential for abuse and dependence.
See also[edit]
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
